COMMENTARY: The real story behind Trump’s GLP-1 price cut: Markets still rule

President Donald Trump just announced deals with drugmakers Eli Lilly and Novo Nordisk that will yield lower prices for GLP-1 ...

Ozempic Enters India: Diabetes Drug, Not A Miracle Fix, Novo Nordisk MD To NDTV

In an exclusive interaction with NDTV, Managing Director of Novo Nordisk India, Vikrant Shrotriya, said the launch of ...

WHO releases new guidance for GLP-1 weight loss drugs: What to know

The World Health Organization issued new guidance this week on the use of popular GLP-1 drugs, like Ozempic, Wegovy, Mounjaro ...
Medical Dialogues

Novo Nordisk Gets CDSCO Panel Nod to Update Wegovy Label With New Safety, Pharmacodynamics Data

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has recommended granting approval to Novo Nordisk India for its proposed update to ...
MiBolsilloColombia on MSN

Medicare: List of 15 commonly used drugs that will be cheaper in 2026

Medicare beneficiaries will see major pricing shifts as federal negotiations reshape how costly prescription drugs are paid ...

Who Should Avoid Ozempic? Doctor Explains Why The Drug Is Not For Everyone

Ozempic can be beneficial for a lot of people, however, some people should avoid it. Read on to know why the drug is not for ...
The Financial Express

Ozempic pricing explained: Novo Nordisk India Head says, ‘we’ll drive science and stay competitive’

Vikrant Shrotriya, Novo Nordisk India MD responds to questions on future pricing, generics competition post patent expiry in March, Indian-specific pricing, demand in India & quality. “India is not a ...